NEURALAGENT
3.6.2024 10:01:27 CEST | Business Wire | Press release
Airbus Defence and Space, a leader in the aerospace industry, and NeuralAgent, an innovative AI start-up, have signed two contracts that will help shape the Future Combat Air System (FCAS) programme. This tri-national programme led by the Ministries of Defence from France, Germany and Spain marks a significant step forward in strengthening European Defence Systems, notably through cutting-edge artificial intelligence. This partnership between Airbus and NeuralAgent will contribute to the FCAS’ Combat Cloud, as part of the global phase 1B contract.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530772952/en/
Figure 1: Signing Ceremony, People from left to right, Jennifer Klaschka- Marketing and Operations at NeuralAgent, Dr. -Ing Onur Deniz CEO at NeuralAgent, Dirk Sprünken Procurement at Airbus, Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus, Luis Mager – Procurement at Airbus (Photo: Business Wire)
The partnership focuses on bridging the innovation gap with an AI-defined, non-jammable, resilient, and self-organizing network and system architectures in the air, on the ground or in space. The aim is to automate and optimize the response times of an unlimited number of combat nodes, reducing them to real time or milliseconds. This initiative will leverage Airbus Defence and Space's advanced infrastructure and NeuralAgent’s cutting-edge decentralized AI technology to deliver redundant, explainable, and high-performant collaborative Agents under dynamic environments. This aims to outperform costly central AI-Approaches with a single point of failure against jamming. Together, they seek to transform defense capabilities with unprecedented and distributed autonomous intelligence of large number of combat nodes.
Dr. -Ing Onur Deniz, CEO of NeuralAgent, emphasized the importance of this collaboration: "This contract is a pivotal achievement for NeuralAgent as it allows us to not only redefine the future of AI-defined Secure and Resilient Networks through our foundational AI-Agent Models but also extends our reach into dual-use cases for commercial industries from space to ground, supporting scalable innovation across the EU."
Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus Defence and Space, highlighted the benefits of this partnership: "Working with disruptive AI start-ups such as NeuralAgent, will propel our innovation efforts and help us stay ahead with the latest AI trends. This collaboration will enhance our capabilities in both legacy and future systems, ensuring we remain at the forefront of technological advancements."
This strategic partnership between Airbus Defence and Space and NeuralAgent aims to transform European defense AI capabilities, showcasing their commitment to innovation and leadership in the EU's biggest defense project.
About Airbus Defence and Space
Airbus Defence and Space is a division of Airbus Group responsible for defence and aerospace products and services. The company is a leader in designing, developing, and manufacturing military aircraft, space systems, and connected intelligence systems and services.
About NeuralAgent
NeuralAgent is an AI start-up specializing in the development of Decentralized AI-Agent Foundation Models for distributed autonomous intelligence and shaping the future of Telecoms, Mobility, NewSpace, Robotics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530772952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom